BIOVF
Price
$29.18
Change
-$1.38 (-4.52%)
Updated
Sep 4 closing price
Capitalization
10.02B
SFOSF
Price
$2.85
Change
+$0.01 (+0.35%)
Updated
Sep 4 closing price
Capitalization
10.66B
Interact to see
Advertisement

BIOVF vs SFOSF

Header iconBIOVF vs SFOSF Comparison
Open Charts BIOVF vs SFOSFBanner chart's image
Swedish Orphan Biovitrum AB
Price$29.18
Change-$1.38 (-4.52%)
Volume$300
Capitalization10.02B
Shanghai Fosun Pharmaceutical Group
Price$2.85
Change+$0.01 (+0.35%)
Volume$120
Capitalization10.66B
BIOVF vs SFOSF Comparison Chart in %
Loading...
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SFOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIOVF vs. SFOSF commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOVF is a Hold and SFOSF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (BIOVF: $29.18 vs. SFOSF: $2.85)
Brand notoriety: BIOVF and SFOSF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BIOVF: 97% vs. SFOSF: 13%
Market capitalization -- BIOVF: $10.02B vs. SFOSF: $10.66B
BIOVF [@Pharmaceuticals: Generic] is valued at $10.02B. SFOSF’s [@Pharmaceuticals: Generic] market capitalization is $10.66B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIOVF’s FA Score shows that 0 FA rating(s) are green whileSFOSF’s FA Score has 1 green FA rating(s).

  • BIOVF’s FA Score: 0 green, 5 red.
  • SFOSF’s FA Score: 1 green, 4 red.
According to our system of comparison, SFOSF is a better buy in the long-term than BIOVF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIOVF’s TA Score shows that 3 TA indicator(s) are bullish while SFOSF’s TA Score has 3 bullish TA indicator(s).

  • BIOVF’s TA Score: 3 bullish, 5 bearish.
  • SFOSF’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, SFOSF is a better buy in the short-term than BIOVF.

Price Growth

BIOVF (@Pharmaceuticals: Generic) experienced а -4.52% price change this week, while SFOSF (@Pharmaceuticals: Generic) price change was +23.91% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SFOSF($10.7B) has a higher market cap than BIOVF($10B). BIOVF has higher P/E ratio than SFOSF: BIOVF (21.80) vs SFOSF (16.69). SFOSF YTD gains are higher at: 58.307 vs. BIOVF (5.495). BIOVF has higher annual earnings (EBITDA): 9.77B vs. SFOSF (5.91B). SFOSF has more cash in the bank: 16.1B vs. BIOVF (1.06B). BIOVF has less debt than SFOSF: BIOVF (12.8B) vs SFOSF (36.2B). SFOSF has higher revenues than BIOVF: SFOSF (40.3B) vs BIOVF (27B).
BIOVFSFOSFBIOVF / SFOSF
Capitalization10B10.7B93%
EBITDA9.77B5.91B165%
Gain YTD5.49558.3079%
P/E Ratio21.8016.69131%
Revenue27B40.3B67%
Total Cash1.06B16.1B7%
Total Debt12.8B36.2B35%
FUNDAMENTALS RATINGS
BIOVF vs SFOSF: Fundamental Ratings
BIOVF
SFOSF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
55100
SMR RATING
1..100
6582
PRICE GROWTH RATING
1..100
7538
P/E GROWTH RATING
1..100
9651
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SFOSF's Valuation (25) in the null industry is somewhat better than the same rating for BIOVF (79). This means that SFOSF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

BIOVF's Profit vs Risk Rating (55) in the null industry is somewhat better than the same rating for SFOSF (100). This means that BIOVF’s stock grew somewhat faster than SFOSF’s over the last 12 months.

BIOVF's SMR Rating (65) in the null industry is in the same range as SFOSF (82). This means that BIOVF’s stock grew similarly to SFOSF’s over the last 12 months.

SFOSF's Price Growth Rating (38) in the null industry is somewhat better than the same rating for BIOVF (75). This means that SFOSF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

SFOSF's P/E Growth Rating (51) in the null industry is somewhat better than the same rating for BIOVF (96). This means that SFOSF’s stock grew somewhat faster than BIOVF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIOVFSFOSF
RSI
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 4 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
50%
Bearish Trend 4 days ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
57%
Bullish Trend 4 days ago
45%
MACD
ODDS (%)
Bearish Trend 4 days ago
40%
Bullish Trend 4 days ago
53%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
46%
Bullish Trend 4 days ago
51%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
41%
Bullish Trend 4 days ago
45%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
57%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
36%
N/A
Aroon
ODDS (%)
Bullish Trend 7 days ago
61%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BIOVF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SFOSF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QMNV22.020.02
+0.09%
FT Vest Nasdaq-100® Mod Buffr ETF – Nov
QPFF35.740.03
+0.07%
American Century Quality Preferred ETF
DIVZ35.77-0.01
-0.03%
Opal Dividend Income ETF
PJUN40.69-0.02
-0.05%
Innovator U.S. Equity Power BffrETF™-Jun
IUSV98.55-0.42
-0.42%
iShares Core S&P US Value ETF

BIOVF and

Correlation & Price change

A.I.dvisor tells us that BIOVF and SFOSF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOVF and SFOSF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIOVF
1D Price
Change %
BIOVF100%
N/A
SFOSF - BIOVF
21%
Poorly correlated
N/A
BIOYF - BIOVF
7%
Poorly correlated
-1.39%
BOIRF - BIOVF
1%
Poorly correlated
N/A
ARSUF - BIOVF
1%
Poorly correlated
N/A
BKUH - BIOVF
0%
Poorly correlated
N/A
More

SFOSF and

Correlation & Price change

A.I.dvisor tells us that SFOSF and BIOVF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SFOSF and BIOVF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SFOSF
1D Price
Change %
SFOSF100%
N/A
BIOVF - SFOSF
21%
Poorly correlated
N/A
TKPHF - SFOSF
7%
Poorly correlated
+11.86%
PHCUF - SFOSF
7%
Poorly correlated
N/A
SGIOF - SFOSF
5%
Poorly correlated
N/A
TCNNF - SFOSF
3%
Poorly correlated
+4.55%
More